|
US459007A
(en)
|
|
1891-09-08 |
|
Porte |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
US4364935A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
|
EP0271581B1
(en)
|
1986-04-17 |
1993-01-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel compounds dc-88a and dc-89a1 and process for their preparation
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
|
US5084468A
(en)
|
1988-08-11 |
1992-01-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Dc-88a derivatives
|
|
JP2598116B2
(ja)
|
1988-12-28 |
1997-04-09 |
協和醗酵工業株式会社 |
新規物質ｄｃ１１３
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP2510335B2
(ja)
|
1989-07-03 |
1996-06-26 |
協和醗酵工業株式会社 |
Ｄｃ―８８ａ誘導体
|
|
US5187186A
(en)
|
1989-07-03 |
1993-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrroloindole derivatives
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
AU652936B2
(en)
|
1990-05-07 |
1994-09-15 |
Scripps Clinic And Research Foundation |
Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
|
|
US5968509A
(en)
|
1990-10-05 |
1999-10-19 |
Btp International Limited |
Antibodies with binding affinity for the CD3 antigen
|
|
CZ333796A3
(cs)
|
1991-03-06 |
1998-06-17 |
MERCK Patent Gesellschaft mit beschränkter Haftung |
Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
|
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
CA2076465C
(en)
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US6329507B1
(en)
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5837242A
(en)
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
WO1994013806A1
(en)
|
1992-12-11 |
1994-06-23 |
The Dow Chemical Company |
Multivalent single chain antibodies
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5767237A
(en)
|
1993-10-01 |
1998-06-16 |
Teikoku Hormone Mfg. Co., Ltd. |
Peptide derivatives
|
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
|
WO1995029179A1
(en)
|
1994-04-22 |
1995-11-02 |
Kyowa Hakko Kogyo Co., Ltd. |
Dc-89 derivative
|
|
JPH07309761A
(ja)
|
1994-05-20 |
1995-11-28 |
Kyowa Hakko Kogyo Co Ltd |
デュオカルマイシン誘導体の安定化法
|
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5550246A
(en)
|
1994-09-07 |
1996-08-27 |
The Scripps Research Institute |
Calicheamicin mimics
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
JPH11507535A
(ja)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7696338B2
(en)
|
1995-10-30 |
2010-04-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin fusion proteins and means for expression thereof
|
|
ES2195036T3
(es)
|
1995-12-22 |
2003-12-01 |
Bristol Myers Squibb Co |
Conectores de hidrazona ramificados.
|
|
WO1997024373A1
(en)
|
1995-12-29 |
1997-07-10 |
Medvet Science Pty. Limited |
Monoclonal antibody antagonists to haemopoietic growth factors
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
AUPN999096A0
(en)
|
1996-05-22 |
1996-06-13 |
Northstar Biologicals Pty Ltd |
Peptides, antibodies, vaccines & uses thereof
|
|
EP0915987A2
(en)
|
1997-04-21 |
1999-05-19 |
Donlar Corporation |
POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
ATE299938T1
(de)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
DE69922159T2
(de)
|
1998-01-23 |
2005-12-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Mehrzweck-antikörperderivate
|
|
DK2180007T4
(da)
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
|
TR200003087T2
(tr)
|
1998-04-21 |
2001-02-21 |
Micromet Ag |
Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
ATE460946T1
(de)
*
|
1998-06-22 |
2010-04-15 |
Immunomedics Inc |
Gebrauch von bispezifischen antikörpern in diagnose und therapie
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
DK1176195T3
(da)
|
1999-04-09 |
2013-06-24 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
|
|
US6939545B2
(en)
|
1999-04-28 |
2005-09-06 |
Genetics Institute, Llc |
Composition and method for treating inflammatory disorders
|
|
CA2589418A1
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
WO2001024763A2
(en)
|
1999-10-01 |
2001-04-12 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
WO2001029246A1
(fr)
|
1999-10-19 |
2001-04-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'un polypeptide
|
|
US6716410B1
(en)
|
1999-10-26 |
2004-04-06 |
The Regents Of The University Of California |
Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
|
|
PL357448A1
(en)
|
2000-02-25 |
2004-07-26 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
|
|
US7449443B2
(en)
|
2000-03-23 |
2008-11-11 |
California Institute Of Technology |
Method for stabilization of proteins using non-natural amino acids
|
|
US20010035606A1
(en)
|
2000-03-28 |
2001-11-01 |
Schoen Alan H. |
Set of blocks for packing a cube
|
|
CA2407956A1
(en)
|
2000-05-03 |
2001-11-08 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
ES2259030T3
(es)
|
2000-05-19 |
2006-09-16 |
Scancell Limited |
Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
|
|
EP1299419A2
(en)
|
2000-05-24 |
2003-04-09 |
Imclone Systems, Inc. |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
|
AU2001283496A1
(en)
|
2000-07-25 |
2002-02-05 |
Immunomedics, Inc. |
Multivalent target binding protein
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
|
EA013224B1
(ru)
|
2000-10-06 |
2010-04-30 |
Киова Хакко Кирин Ко., Лтд. |
Клетки, продуцирующие композиции антител
|
|
JPWO2002030954A1
(ja)
|
2000-10-06 |
2004-02-19 |
協和醗酵工業株式会社 |
抗体を精製する方法
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20020147312A1
(en)
|
2001-02-02 |
2002-10-10 |
O'keefe Theresa |
Hybrid antibodies and uses thereof
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
AU2002307037B2
(en)
|
2001-04-02 |
2008-08-07 |
Biogen Idec Inc. |
Recombinant antibodies coexpressed with GnTIII
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
KR20030033007A
(ko)
|
2001-05-31 |
2003-04-26 |
코울터 파머수티컬, 인코포레이티드 |
세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
|
|
JP4298498B2
(ja)
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー／エス |
上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
|
|
JP2003111595A
(ja)
*
|
2001-06-25 |
2003-04-15 |
Kyogo Ito |
腫瘍抗原
|
|
US20040242851A1
(en)
|
2001-06-26 |
2004-12-02 |
Zhenping Zhu |
Bispecific antibodies that bind to vegf receptors
|
|
US6513428B1
(en)
|
2001-07-23 |
2003-02-04 |
Heidelberger Druckmaschinen Ag |
Device and method for attaching a printing web to a webbing sail and device and method for webbing-up a printing machine
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
WO2003068821A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US7139665B2
(en)
|
2002-02-27 |
2006-11-21 |
California Institute Of Technology |
Computational method for designing enzymes for incorporation of non natural amino acids into proteins
|
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
CA2484000A1
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
|
PT2357006E
(pt)
|
2002-07-31 |
2016-01-22 |
Seattle Genetics Inc |
Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
WO2004043493A1
(en)
|
2002-11-14 |
2004-05-27 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
|
DK1578397T3
(da)
|
2002-11-15 |
2013-03-11 |
Genmab As |
Humane monoklonale antistoffer mod CD25
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
SI1651162T1
(sl)
|
2003-05-20 |
2016-02-29 |
Immunogen, Inc. |
Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CA2522586C
(en)
|
2003-05-31 |
2017-02-21 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
|
BRPI0410338A
(pt)
|
2003-05-31 |
2006-05-30 |
Micromet Ag |
composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
|
|
US7888134B2
(en)
|
2003-06-05 |
2011-02-15 |
Oakland University |
Immunosensors: scFv-linker design for surface immobilization
|
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
EP2322569B1
(en)
|
2003-10-09 |
2020-08-26 |
Ambrx, Inc. |
Polymer derivatives for the selective modification of proteins
|
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
|
PT1725249E
(pt)
|
2003-11-06 |
2014-04-10 |
Seattle Genetics Inc |
Compostos de monometilvalina capazes de conjugação a ligandos
|
|
WO2005056759A2
(en)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
JP2008504007A
(ja)
|
2003-12-19 |
2008-02-14 |
ジェネンテック・インコーポレーテッド |
治療薬として有用な一価抗体断片
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
CA2553035A1
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
|
PT2511297E
(pt)
|
2004-02-06 |
2015-08-24 |
Morphosys Ag |
Anticorpos humanos anti-cd38 e utilizações dos mesmos
|
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
AU2005244751A1
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting B cell depletion
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
CA2564076C
(en)
|
2004-05-19 |
2014-02-18 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
US20060018897A1
(en)
|
2004-06-28 |
2006-01-26 |
Transtarget Inc. |
Bispecific antibodies
|
|
CN102702353A
(zh)
|
2004-07-09 |
2012-10-03 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
|
ZA200701783B
(en)
|
2004-09-02 |
2009-10-28 |
Genentech Inc |
Anti-Fc-gamma RIIB receptor antibody and uses therefor
|
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
|
ES2629397T3
(es)
|
2004-09-24 |
2017-08-09 |
Amgen Inc. |
Moléculas de Fc modificadas
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8066989B2
(en)
|
2004-11-30 |
2011-11-29 |
Trion Pharma Gmbh |
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
|
ES2320374T3
(es)
|
2005-01-05 |
2009-05-21 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
|
|
EP1847602B1
(en)
|
2005-01-12 |
2014-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG2 ANTIBODIES
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2006124641A2
(en)
|
2005-05-12 |
2006-11-23 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Anti-mesothelin antibodies useful for immunological assays
|
|
RS52861B
(sr)
|
2005-06-07 |
2013-12-31 |
Esbatech - A Novartis Company Llc |
Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
|
|
WO2007023390A2
(en)
|
2005-07-01 |
2007-03-01 |
Dako Denmark A/S |
Immunohistochemistry detection method
|
|
WO2007005612A2
(en)
|
2005-07-01 |
2007-01-11 |
Medimmune, Inc. |
An integrated approach for generating multidomain protein therapeutics
|
|
CN101267836A
(zh)
|
2005-07-25 |
2008-09-17 |
特鲁比昂药品公司 |
单剂量cd20特异性结合分子的用途
|
|
UA97469C2
(uk)
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
|
CA2617907A1
(en)
|
2005-08-05 |
2007-02-15 |
Syntarga B.V. |
Triazole-containing releasable linkers and conjugates comprising the same
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
AR057807A1
(es)
|
2005-09-12 |
2007-12-19 |
Novimmune Sa |
Formulaciones de anticuerpo anti-cd3
|
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
ES2856451T3
(es)
|
2005-10-11 |
2021-09-27 |
Amgen Res Munich Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
|
|
SI2860192T1
(en)
|
2005-10-12 |
2018-04-30 |
Morphosys Ag |
Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38
|
|
US7790655B2
(en)
|
2005-10-14 |
2010-09-07 |
Medimmune, Llc |
Cell display of antibody libraries
|
|
WO2007047829A2
(en)
|
2005-10-19 |
2007-04-26 |
Laboratoires Serono S.A. |
Novel heterodimeric proteins and uses thereof
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
JP2009516513A
(ja)
|
2005-11-21 |
2009-04-23 |
ラボラトワール セローノ ソシエテ アノニム |
ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
|
|
EP1981532A4
(en)
|
2005-12-21 |
2010-06-30 |
Medimmune Llc |
EPHA2 MOLECULES AND USES THEREOF
|
|
EP1984505B1
(en)
|
2006-01-13 |
2019-12-25 |
The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
|
KR20080114709A
(ko)
|
2006-02-02 |
2008-12-31 |
신타가 비.브이. |
수용성 ｃｃ-1065 유사체 및 그들의 결합체
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
BRPI0709598A8
(pt)
|
2006-03-17 |
2019-01-08 |
Biogen Idec Inc |
composições de polipeptídeos estabilizados
|
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
|
EP2007423A2
(en)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
WO2008042754A2
(en)
|
2006-10-02 |
2008-04-10 |
Sea Lane Biotechnologies, Llc |
Design and construction of diverse synthetic peptide and polypeptide libraries
|
|
US7795411B2
(en)
|
2006-10-05 |
2010-09-14 |
Fred Hutchinson Cancer Research Center |
Vectors for expressing in vivo biotinylated recombinant proteins
|
|
ES2526292T3
(es)
|
2006-10-16 |
2015-01-09 |
The Salk Institute For Biological Studies |
Antagonistas de la somatostatina selectivos para receptor (SSTR2)
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0624500D0
(en)
|
2006-12-07 |
2007-01-17 |
Istituto Superiore Di Sanito |
A novel passive vaccine for candida infections
|
|
US7862825B2
(en)
|
2007-02-21 |
2011-01-04 |
Mladen Vranic |
Method of controlling tight blood glucose by somatostatin receptor antagonists
|
|
US8114967B2
(en)
|
2007-03-27 |
2012-02-14 |
Sea Lane Biotechnologies Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
EP1975178A1
(en)
|
2007-03-30 |
2008-10-01 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Transcytotic modular antibody
|
|
EP4059964A1
(en)
|
2007-04-03 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific binding domain
|
|
CN101675077B
(zh)
|
2007-04-03 |
2013-09-04 |
安进研发（慕尼黑）股份有限公司 |
跨种特异性的双特异性结合剂
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
|
EP2158318A2
(en)
|
2007-05-14 |
2010-03-03 |
Biogen Idec MA, Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP2666787B1
(en)
|
2007-05-31 |
2022-02-09 |
Genmab A/S |
STABLE IgG4 ANTIBODIES
|
|
KR20100044160A
(ko)
|
2007-06-12 |
2010-04-29 |
와이어쓰 엘엘씨 |
항-ｃｄ20 치료 조성물 및 방법
|
|
KR101562580B1
(ko)
|
2007-06-18 |
2015-10-22 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
JP5602625B2
(ja)
|
2007-06-26 |
2014-10-08 |
エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング |
結合物質のディスプレイ
|
|
WO2009017823A2
(en)
|
2007-08-01 |
2009-02-05 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
WO2009017394A1
(en)
|
2007-08-01 |
2009-02-05 |
Syntarga B.V. |
Substituted cc-1065 analogs and their conjugates
|
|
AU2008296386A1
(en)
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Compositions that bind multiple epitopes of IGF-1R
|
|
EP2033657A1
(de)
|
2007-09-04 |
2009-03-11 |
Trion Pharma Gmbh |
Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
|
|
US20100226925A1
(en)
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
|
KR102467302B1
(ko)
|
2007-09-26 |
2022-11-14 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
EP2535350B1
(en)
*
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
|
EP2235059B1
(en)
|
2007-12-26 |
2015-02-18 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
AU2009204501B2
(en)
|
2008-01-07 |
2015-02-12 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
|
WO2009106096A1
(en)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Treatment of resistant tumors with trifunctional antibodies
|
|
NZ621443A
(en)
|
2008-04-11 |
2015-09-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US8314213B2
(en)
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CN101628940B
(zh)
*
|
2008-07-15 |
2011-11-23 |
中国科学院生物物理研究所 |
一种单克隆抗体及其应用
|
|
KR20110050541A
(ko)
|
2008-08-29 |
2011-05-13 |
심포젠 에이/에스 |
항-ｃｄ５ 항체
|
|
WO2010028796A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Trispecific hexavalent antibodies
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US20170247470A9
(en)
|
2008-09-17 |
2017-08-31 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
KR101783272B1
(ko)
|
2008-09-17 |
2017-09-29 |
젠코어 인코포레이티드 |
ＩｇＥ-매개된 장애를 치료하기 위한 신규 조성물 및 방법
|
|
CN102164960A
(zh)
|
2008-09-26 |
2011-08-24 |
罗氏格黎卡特股份公司 |
双特异性抗-egfr/抗-igf-1r抗体
|
|
WO2010037837A2
(en)
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
NZ591087A
(en)
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
JP6126782B2
(ja)
|
2008-10-01 |
2017-05-10 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
|
|
EP3375790A1
(en)
|
2008-10-01 |
2018-09-19 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
US20110217302A1
(en)
|
2008-10-10 |
2011-09-08 |
Emergent Product Development Seattle, Llc |
TCR Complex Immunotherapeutics
|
|
HUE035798T2
(en)
|
2008-11-03 |
2018-05-28 |
Syntarga Bv |
CC-1065 analogues and conjugates
|
|
EP2389192A4
(en)
|
2009-01-23 |
2013-01-16 |
Biogen Idec Inc |
STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
PE20120359A1
(es)
|
2009-03-06 |
2012-04-13 |
Genentech Inc |
Formulacion con anticuerpo
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
CA2757669A1
(en)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Bispecific anti-erbb-1/anti-c-met antibodies
|
|
EP2417156B1
(en)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalent, bispecific antibodies
|
|
BRPI1012589A2
(pt)
|
2009-04-07 |
2016-03-22 |
Roche Glycart Ag |
anticorpos bi-específicos anti-erbb-3/anti-c-met
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
CA2761233A1
(en)
|
2009-05-27 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
|
CN102498210B
(zh)
|
2009-06-26 |
2015-07-29 |
航道生物技术有限责任公司 |
替代轻链的表达
|
|
EP2975051B1
(en)
|
2009-06-26 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
MX2011013455A
(es)
|
2009-07-08 |
2012-02-13 |
Amgen Inc |
Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
|
KR101841781B1
(ko)
|
2009-10-27 |
2018-03-23 |
암젠 리서치 (뮌헨) 게엠베하 |
ＣＤ１９ｘＣＤ３ 이중특이적 항체를 투여하는 투약 용법
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
PT2506871T
(pt)
|
2009-11-30 |
2016-11-07 |
Janssen Biotech Inc |
Mutantes de fc de anticorpos com funções efetoras inutilizadas
|
|
BR112012017124C1
(pt)
|
2009-12-25 |
2021-08-31 |
Chugai Pharmaceutical Co Ltd |
Método para produzir e para purificar um multímero polipeptídico
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
JP5856073B2
(ja)
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
Ｒｏｎ結合構築体およびその使用方法
|
|
US20110189178A1
(en)
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
|
NZ631363A
(en)
|
2010-02-08 |
2016-05-27 |
Regeneron Pharma |
Common light chain mouse
|
|
CN102971340A
(zh)
|
2010-03-29 |
2013-03-13 |
酵活有限公司 |
具有增强的或抑制的效应子功能的抗体
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
LT2560993T
(lt)
|
2010-04-20 |
2024-10-10 |
Genmab A/S |
Baltymai, kurių sudėtyje yra heterodimerinio antikūno fc, ir jų gamybos būdai
|
|
BR112012027001A2
(pt)
|
2010-04-23 |
2016-07-19 |
Genentech Inc |
produção de proteínas heteromultiméricas
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
PL2580243T3
(pl)
|
2010-06-09 |
2020-05-18 |
Genmab A/S |
Przeciwciała przeciwko ludzkiemu CD38
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
DK3029066T3
(da)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
Antistoffer med modificerede isoelektriske punkter
|
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
JP5758004B2
(ja)
*
|
2010-08-24 |
2015-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
|
US10130638B2
(en)
|
2010-11-10 |
2018-11-20 |
Amgen Research (Munich) Gmbh |
Prevention of adverse effects caused by CD3 specific binding domains
|
|
CN103282385A
(zh)
|
2010-11-12 |
2013-09-04 |
美国洛克菲勒大学 |
用于hiv治疗的融合蛋白
|
|
FI3434767T3
(fi)
|
2010-11-30 |
2026-02-12 |
Chugai Seiyaku Kk |
Sytotoksisuutta aiheuttava terapeuttinen aine
|
|
MX340671B
(es)
|
2011-02-10 |
2016-07-20 |
Roche Glycart Ag |
Polipeptidos interleuquina- 2 mutantes.
|
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
JP2014517683A
(ja)
|
2011-03-11 |
2014-07-24 |
アムジェン インコーポレイテッド |
治療抗体を改善する相関突然変異分析の方法
|
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
|
CN103429619B
(zh)
|
2011-03-17 |
2017-07-28 |
雷蒙特亚特特拉维夫大学有限公司 |
双特异性和单特异性、不对称抗体和其制备方法
|
|
MX358752B
(es)
|
2011-03-25 |
2018-08-31 |
Glenmark Pharmaceuticals Sa |
Inmunoglobulinas heterodiméricas.
|
|
TWI622597B
(zh)
|
2011-03-28 |
2018-05-01 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
TR201815420T4
(tr)
|
2011-03-29 |
2018-11-21 |
Roche Glycart Ag |
Antikor fc varyantları.
|
|
ES2666550T3
(es)
|
2011-04-19 |
2018-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
|
|
WO2012146394A1
(en)
|
2011-04-28 |
2012-11-01 |
Amgen Research (Munich) Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
MY173899A
(en)
|
2011-05-21 |
2020-02-26 |
Macrogenics Inc |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
CN103582650A
(zh)
|
2011-05-25 |
2014-02-12 |
默沙东公司 |
用于制备具有改善性质的含Fc多肽的方法
|
|
EP2729488A4
(en)
|
2011-07-06 |
2015-01-14 |
Medimmune Llc |
PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
|
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
|
TR201802089T4
(tr)
|
2011-08-04 |
2018-03-21 |
Toray Industries |
Kanserin tedavisi ve/veya önlenmesi amacına yönelik ilaç bileşimi.
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
CN103890246A
(zh)
|
2011-08-18 |
2014-06-25 |
亲和生物科学公司 |
可溶性多肽
|
|
DK2748201T3
(en)
|
2011-08-23 |
2018-02-12 |
Roche Glycart Ag |
BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES
|
|
JP2015527869A
(ja)
|
2011-08-26 |
2015-09-24 |
メリマック ファーマシューティカルズ インコーポレーティッド |
タンデムＦｃ二重特異性抗体
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
WO2013055809A1
(en)
|
2011-10-10 |
2013-04-18 |
Xencor, Inc. |
A method for purifying antibodies
|
|
US10851178B2
(en)
*
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
UY34404A
(es)
|
2011-10-20 |
2013-05-31 |
Esbatech A Novartis Co Llc |
Anticuerpo estable unido a múltiples antígenos
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
JP6371059B2
(ja)
|
2011-10-31 |
2018-08-08 |
中外製薬株式会社 |
重鎖と軽鎖の会合が制御された抗原結合分子
|
|
HUE056462T2
(hu)
|
2011-11-04 |
2022-02-28 |
Zymeworks Inc |
Stabil heterodimer antestest tervezés mutációkkal az FC domainben
|
|
WO2013070565A1
(en)
*
|
2011-11-07 |
2013-05-16 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
|
US20140212425A1
(en)
*
|
2011-12-05 |
2014-07-31 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
US9718893B2
(en)
|
2011-12-19 |
2017-08-01 |
Synimmune Gmbh |
Bispecific antibody molecule
|
|
WO2013096828A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
|
TWI617577B
(zh)
|
2012-02-24 |
2018-03-11 |
中外製藥股份有限公司 |
經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
|
|
ES2740749T3
(es)
|
2012-04-20 |
2020-02-06 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
MY174248A
(en)
|
2012-04-30 |
2020-04-01 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
SMT202200295T1
(it)
*
|
2012-05-18 |
2022-09-14 |
Aptevo Res & Development Llc |
Immunofusione bispecifica (bif) di scfv legante cd123 e cd3
|
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
KR20150036606A
(ko)
|
2012-07-13 |
2015-04-07 |
자임워크스 인코포레이티드 |
항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
|
|
CA2878587A1
(en)
|
2012-07-23 |
2014-01-30 |
Zymeworks Inc. |
Immunoglobulin constructs comprising selective pairing of the light and heavy chains
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
WO2014055897A2
(en)
|
2012-10-04 |
2014-04-10 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
|
|
WO2014078866A2
(en)
*
|
2012-11-19 |
2014-05-22 |
Xencor, Inc. |
Engineered immunoglobulins with extended in vivo half-life
|
|
WO2014079000A1
(en)
|
2012-11-21 |
2014-05-30 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
CN104955953B
(zh)
*
|
2012-11-27 |
2019-04-26 |
亚洲大学校产学协力团 |
高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对，其制备方法及用途
|
|
WO2014100490A1
(en)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Multivalent antibody analogs, and methods of their preparation and use
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
*
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
*
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10968276B2
(en)
*
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
*
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
EP2762497A1
(en)
*
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
WO2014138449A1
(en)
|
2013-03-06 |
2014-09-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
|
CA2904969C
(en)
|
2013-03-13 |
2025-06-17 |
Imaginab, Inc. |
DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US11634502B2
(en)
|
2013-03-15 |
2023-04-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HRP20191470T1
(hr)
*
|
2013-03-15 |
2020-01-10 |
Xencor, Inc. |
Heterodimerni proteini
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
HRP20231437T1
(hr)
|
2013-08-08 |
2024-02-16 |
Cytune Pharma |
Il-15 i il-15ralpha sushi domena na temelju modulokina
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
US10258887B2
(en)
|
2013-10-25 |
2019-04-16 |
Voyetra Turtle Beach, Inc. |
Method and system for a headset with parental control
|
|
MY176522A
(en)
|
2013-11-04 |
2020-08-13 |
Ichnos Sciences SA |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
WO2015095410A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
JP2017501167A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
|
|
HRP20240939T1
(hr)
|
2013-12-17 |
2024-10-25 |
Genentech, Inc. |
Anti-cd3 protutijela i metode uporabe
|
|
MX2016008667A
(es)
|
2013-12-30 |
2017-02-02 |
Epimab Biotherapeutics Inc |
Inmunoglobulina con fab en tandem y usos de esta.
|
|
AU2014377106B2
(en)
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
GB201402631D0
(en)
|
2014-02-14 |
2014-04-02 |
Alligator Bioscience Ab |
Library
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
RU2577226C2
(ru)
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
|
EP3137105A4
(en)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
|
AP2016009586A0
(en)
|
2014-05-29 |
2016-11-30 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
|
WO2016014984A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
WO2016020856A2
(en)
|
2014-08-05 |
2016-02-11 |
MabQuest SA |
Immunological reagents
|
|
TW202140557A
(zh)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
ES2890669T3
(es)
|
2014-09-09 |
2022-01-21 |
Janssen Biotech Inc |
Terapias de combinación con anticuerpos anti-CD38
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
MA40894A
(fr)
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
CN107206072B
(zh)
|
2014-11-20 |
2022-01-21 |
豪夫迈·罗氏有限公司 |
T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD-1轴结合拮抗剂的组合疗法
|
|
US10526417B2
(en)
|
2014-11-26 |
2020-01-07 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
|
AU2015353409B2
(en)
|
2014-11-26 |
2019-05-09 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
CA2874083C
(en)
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
SMT201900702T1
(it)
|
2015-01-08 |
2020-01-14 |
Genmab As |
Agenti agonistici leganti il recettore del tnf
|
|
AU2016206707A1
(en)
|
2015-01-14 |
2017-08-10 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
PH12017502019B1
(en)
*
|
2015-05-08 |
2023-09-20 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
WO2016210223A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
GEAP202215554A
(en)
|
2015-07-30 |
2022-06-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
EP3331902B1
(en)
|
2015-08-07 |
2021-04-28 |
ALX Oncology Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
CA2996060A1
(en)
|
2015-08-21 |
2017-03-02 |
Carsgen Therapeutics, Ltd |
Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
|
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
WO2017072366A1
(en)
|
2015-10-30 |
2017-05-04 |
Nbe-Therapeutics Ag |
Anti-mesothelin antibodies
|
|
US20180305465A1
(en)
|
2015-11-25 |
2018-10-25 |
Amgen Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
MA44146B1
(fr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
MX389710B
(es)
|
2016-05-27 |
2025-03-20 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
|
US20170349657A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
US20170349660A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor. Inc. |
Bispecific antibodies that bind cd123 and cd3
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CN109310762A
(zh)
|
2016-06-07 |
2019-02-05 |
宏观基因有限公司 |
联合疗法
|
|
CN110352070B
(zh)
|
2016-06-14 |
2024-09-17 |
Xencor股份有限公司 |
双特异性检查点抑制剂抗体
|
|
BR112018076281A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
|
|
EP4050032A1
(en)
|
2016-06-28 |
2022-08-31 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
EP3487532A4
(en)
|
2016-07-21 |
2020-03-18 |
Development Center for Biotechnology |
MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME
|
|
EP4273252A3
(en)
|
2016-08-29 |
2024-04-17 |
Akamis Bio Limited |
Adenovirus armed with bispecific t cell engager (bite)
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN107840891A
(zh)
|
2016-09-19 |
2018-03-27 |
上海吉倍生物技术有限公司 |
高亲和力的抗msln抗体及其应用
|
|
CR20230179A
(es)
|
2016-10-14 |
2023-06-12 |
Xencor Inc |
PROTEÍNAS DE FUSIÓN FC HETERODIMÉRICAS IL 15/IL15Ra (Divisional 2019-0229)
|
|
AU2017345454B2
(en)
|
2016-10-19 |
2024-10-31 |
Invenra Inc. |
Antibody constructs
|
|
WO2018129522A1
(en)
|
2017-01-09 |
2018-07-12 |
Torch Therapeutics |
Conditionally effective bispecific therapeutics
|
|
AU2018265860B2
(en)
|
2017-05-12 |
2022-08-11 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
WO2018223004A1
(en)
*
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
US20200181274A1
(en)
*
|
2017-06-01 |
2020-06-11 |
Novartis Ag |
Bispecific antibodies that bind cd 123 cd3
|
|
WO2019050521A1
(en)
|
2017-09-07 |
2019-03-14 |
Macrogenics, Inc. |
DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
|
|
EP3694882B1
(en)
|
2017-10-10 |
2024-06-19 |
Sanofi |
Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
|
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US20200362054A1
(en)
|
2017-11-21 |
2020-11-19 |
Brian Granda |
Trispecific binding molecules against tumor-associated antigents and use thereof
|
|
CA3093078A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
CN113195534A
(zh)
|
2018-04-18 |
2021-07-30 |
Xencor股份有限公司 |
包含il-15/il-15ra fc融合蛋白和lag-3抗原结合结构域的靶向lag-3的异源二聚体融合蛋白
|
|
CN112513085B
(zh)
|
2018-05-24 |
2024-06-18 |
詹森生物科技公司 |
Psma结合剂及其用途
|
|
PE20211091A1
(es)
|
2018-07-02 |
2021-06-14 |
Amgen Inc |
Proteina de union al antigeno anti-steap1
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
JP2021534096A
(ja)
|
2018-08-08 |
2021-12-09 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
WO2021026387A2
(en)
|
2019-08-06 |
2021-02-11 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
|
EP4149975A2
(en)
|
2020-05-13 |
2023-03-22 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
IL300666A
(en)
|
2020-08-19 |
2023-04-01 |
Xencor Inc |
ANTI–CD28 COMPOSITIONS
|
|
US12462008B2
(en)
|
2021-04-23 |
2025-11-04 |
Beijing Boe Technology Development Co., Ltd. |
Unlocking control method and device, electronic apparatus, and computer-readable storage medium
|
|
WO2023196905A1
(en)
|
2022-04-07 |
2023-10-12 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|